We’re proud to share that SILQ Technologies, Inc. and UCLA’s Kaner Group have received the Royal Society of Chemistry’s 2026 Materials Chemistry Horizon Prize. This prestigious international recognition celebrates the development of Silq's zwitterionic polymer surface treatment for medical devices, an innovation designed to help reduce device-associated infections by preventing bacterial attachment without drugs, antimicrobial killing, or traditional antibiotic mechanisms. With catheter-associated urinary tract infections among the most common healthcare-associated infections, and antibiotic resistance continuing to rise, new approaches to infection prevention are urgently needed. We’re especially honored that this award recognizes the power of academic-industry collaboration: foundational chemistry from Professor Richard Kaner’s group at UCLA, paired with SILQ Technologies’ engineering, regulatory, quality, manufacturing, and clinical translation capabilities. Congratulations to the full recognized team: Na He, Richard B. Kaner, Jack Kavanaugh, Min Kyu Lee, Brian T. McVerry, Ethan Rao, and Verne Sharma. Thank you to the Royal Society of Chemistry, our partners, advisors, clinicians, and patients who continue to inspire this work. This milestone strengthens our commitment to advancing infection-resistant medical device technologies for broader patient care. Read more in UCLA’s announcement: https://lnkd.in/gMhrZkQV #MaterialsChemistry #MedicalDevices #SurfaceScience #Zwitterions #HealthcareInnovation #AntibioticResistance #RSCPrizes #AcademicIndustryCollaboration
About us
Silq Technologies is a leader in advanced biomaterials. The company’s patented technology and scalable manufacturing platform deliver a unique surface treatment that is designed to resist the adhesion of organic material, thereby improving the effectiveness, efficiency, and safety of a broad range of commercial products. The technology can be used in medical devices, medical implants, microfluidics, lithium-ion batteries, water treatment facilities, and much more. For additional information, visit https://www.silq.tech/.
- Website
-
https://www.silq.tech/
External link for Silq Technologies
- Industry
- Chemical Manufacturing
- Company size
- 11-50 employees
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Medical Devices, Implants, Foley Catheters, Urology Devices, Water Filtration, Materials Science, Specialty Coatings, Infection Reduction, Drug-Free Medical Solutions, Antimicrobial Resistance, Biofilm Reduction, Surface Technology, Zwitterionic Surface Treatment, and Lubricity
Employees at Silq Technologies
Updates
-
Silq Technologies reposted this
Thrilled to share that Brian will be showcasing Silq's technology and business at LSI '26 in Dana Point on Wednesday, March 18th. If you'd like to connect with Brian during the conference, please send him a private message to set up a time. #LSI2026 #InfectionControl #Infection #InfectionPrevention #MaterialScience #MedTech #MedTechInvesting #SILQ #
Silq Technologies has developed and commercialized an advanced zwitterionic surface-treatment technology that makes implantable and indwelling medical devices resistant to biofilm, encrustation, and protein adhesion—without the use of drugs. The company’s proprietary Silq surface treatment platform integrates bio-inspired chemistry onto device surfaces to reduce infection, inflammation, and device-related complications. Its ClearTract®–branded urinary catheter has received FDA clearance and is supported by multiple clinical studies demonstrating reductions in infection and inflammation, while the broader platform is designed for application across a wide range of implanted and indwelling devices. The company has achieved significant momentum recently, including: • Successfully completed a multi-site, randomized clinical study demonstrating a significant reduction in device-related complications using Silq’s zwitterionic surface treatment. • Executed a strategic collaboration agreement with NuSil Technology, LLC to accelerate broad-based adoption of Silq’s surface treatment across implantable silicone devices. • Secured group purchasing agreements with Vizient, Inc. and Premier, Inc., expanding access to more than 7,500 hospitals nationwide. • Launched more than a dozen evaluation programs with leading OEMs to assess Silq’s technology across single-use, short-term, and long-term implantable devices. We’re excited to announce that CTO Brian McVerry, Ph.D. has been selected to present Silq Technologies at LSI USA ’26 this March 16–20 in Dana Point, California. Connect with Brian onsite to learn more about Silq Technologies.
-
-
Thrilled to share that Brian will be showcasing Silq's technology and business at LSI '26 in Dana Point on Wednesday, March 18th. If you'd like to connect with Brian during the conference, please send him a private message to set up a time. #LSI2026 #InfectionControl #Infection #InfectionPrevention #MaterialScience #MedTech #MedTechInvesting #SILQ #
Silq Technologies has developed and commercialized an advanced zwitterionic surface-treatment technology that makes implantable and indwelling medical devices resistant to biofilm, encrustation, and protein adhesion—without the use of drugs. The company’s proprietary Silq surface treatment platform integrates bio-inspired chemistry onto device surfaces to reduce infection, inflammation, and device-related complications. Its ClearTract®–branded urinary catheter has received FDA clearance and is supported by multiple clinical studies demonstrating reductions in infection and inflammation, while the broader platform is designed for application across a wide range of implanted and indwelling devices. The company has achieved significant momentum recently, including: • Successfully completed a multi-site, randomized clinical study demonstrating a significant reduction in device-related complications using Silq’s zwitterionic surface treatment. • Executed a strategic collaboration agreement with NuSil Technology, LLC to accelerate broad-based adoption of Silq’s surface treatment across implantable silicone devices. • Secured group purchasing agreements with Vizient, Inc. and Premier, Inc., expanding access to more than 7,500 hospitals nationwide. • Launched more than a dozen evaluation programs with leading OEMs to assess Silq’s technology across single-use, short-term, and long-term implantable devices. We’re excited to announce that CTO Brian McVerry, Ph.D. has been selected to present Silq Technologies at LSI USA ’26 this March 16–20 in Dana Point, California. Connect with Brian onsite to learn more about Silq Technologies.
-
-
Dr. Brian McVerry from Silq will be speaking at the 2026 MD&M West Event in Anaheim! Attendees will have the opportunity to explore our innovative surface treatment technology, designed to prevent biofilm formation and reduce the risk of infection on medical implants. #infectionprevention #infection #medtechinnovation #meddevicenews #innovativetechnology #materialscience https://lnkd.in/e8XkYHkP
Excited to announce I'll be speaking at MD&M West 2026 in Anaheim! Join me on February 3rd as I share insights on Silq's pioneering surface treatment to protect implanted medical devices from infection, thrombosis, and fibrosis, without the use of drugs. Looking forward to connecting with fellow innovators in medical device manufacturing and presenting the final results of our randomized clinical studies for the first time. Who else will be there? #MDMWest #Innovation #Manufacturing
-
-
The Neurogenic Bladder Research Group will hold its 2025 Annual Meeting at Rancho Los Amigos National Rehabilitation Center in Downey, CA, from December 12-13. Colleagues nationwide will discuss research, clinical advances, and opportunities for collaboration. Dr. Brian McVerry of Silq will present insights on its surface treatment technology designed to reduce biofilm and infection on medical implants. #MedTech #MedTechInnovation #HealthcareInnovation #MaterialScience #InfectionPrevention #Infection #SILQTechnologies #NBRG
-
-
LSI USA annually gathers 1,500 executives from a broad range of emerging companies and investment organizations, making it a premier event for innovation and leadership in the industry. Silq's Dr. Brian McVerry will present at the next flagship event from March 16 to 20 '26 in Dana Point, California, offering attendees the chance to learn about our surface treatment technology, engineered to prevent biofilm formation and infection on medical implants. https://lnkd.in/g6VtQdXZ #MedTech #MedTechInvesting #HealthcareInnovation #MaterialScience #InfectionPrevention #Infection #SILQTechnologies #LSIUSA
LSI USA ‘26 is already ramping up, and today we’re showcasing the innovators from around the globe who are selected to present in Dana Point, California next March 16-20. Today we’re showcasing: 1. Christopher Haig — Efemoral Medical → Developing a next-generation drug-eluting bioresorbable scaffold for the treatment of PAD. Using a minimally invasive procedure, the Efemoral Vascular Scaffold System is inserted into the leg and expanded inside the artery to restore a channel for blood flow to the foot. The scaffold is strong enough to hold the vessel open, is flexible enough to accommodate the complex skeletal motion of the leg, and elutes a drug to prevent scarring inside the vessel which leads to the need for repeat procedures. The scaffold is naturally absorbed by the body over time, thus leaving behind no permanent implant. 2. Lars Yang — magAssist → Developing advanced solutions for heart failure treatment and circulatory support. Its portfolio includes an interventional artificial heart for PCI procedure protection, which has received U.S. FDA Breakthrough Device Designation, as well as a high-flow, long-duration extracorporeal magnetic levitation heart for acute cardiogenic shock and a magnetic levitation ECMO system. Through its innovations, the company is working to expand treatment options for patients with severe cardiac conditions. 3. Brian McVerry, Ph.D. — Silq Technologies → Developing and commercializing an advanced zwitterionic surface-treatment technology that makes implantable and indwelling medical devices resistant to biofilm, encrustation, and protein adhesion, without the use of drugs. The company has partnered with leading OEMs and healthcare systems to integrate its unique bio-inspired chemistry platform across all implanted medical devices to improve patient outcomes and reduce device-related complications. The company’s proprietary Silq surface treatment - branded as ClearTract® for urinary catheters - has received FDA clearance and is supported by multiple clinical studies demonstrating reductions in infection and inflammation. We look forward to seeing these innovators take the stage! Interested in presenting at LSI USA ‘26? Apply for The Funding Fast Track program today while space is still available.
-
-
Silq Technologies was proud to participate in the Entrepreneurship Section of UCLA’s Exploring Your Universe (EYU) science fair - an inspiring day where thousands of visitors, from curious kids to lifelong learners came together to explore the wonder of science. Hosted in UCLA’s Court of Sciences, EYU is one of Los Angeles County’s largest science outreach events, designed to make STEM accessible and exciting for everyone. From hands-on experiments to telescope viewings, the fair created countless “aha!” moments that remind us why curiosity drives innovation. At Silq, we believe in the power of science to improve lives - whether through cutting-edge infection preventing surface technology or through sparking the next generation’s imagination. It was an honor to share our entrepreneurial journey alongside researchers, students, and fellow innovators working to make science tangible and inspiring. 👏 A huge thank you to the UCLA organizers and volunteers who made this event possible. We’re already looking forward to next year! #STEM #ScienceOutreach #Innovation #UCLA #ExploringYourUniverse #SilqTechnologies #MedTech #Entrepreneurship
-
Across Vancouver, Bellevue, Seattle, and Portland, our Northwest Chapter meeting brought together some of the most inspiring minds in the region. A big thank you to the entrepreneurs who shared their journeys and pitched their ideas- Mike Connolly (Healionics Corporation), D. Verne Sharma (Silq Technologies), Kelley Smith (Kokopelli Packraft), Ed Vincent (festivalPass), Dusty Majumdar, PhD (PredxBio), David T. Scott (Evil Genius Games). You gave us a glimpse into the innovation that’s shaping the future. Our speakers — Kurt Pichler, Michael Stein, Jolene Anderson and Garrett L. — brought real depth and perspective to each forum. Their insights sparked conversations that will continue long after the meeting. And to everyone who joined us, thank you. Your energy, curiosity, and ideas are what make these gatherings so special!
-
-
-
-
-
+3
-
-
We are excited to announce that Verne Sharma, our Chief Executive Officer, has been selected to present SILQ Technologies at the upcoming Keiretsu Forum Northwest Roadshows! At SILQ, we are redefining implant safety through our proprietary anti-microbial surface technology, engineered to prevent biofilm formation and infection on medical implants. Our platform is designed to address a major unmet need in healthcare while unlocking value across multiple medical device markets and beyond. We are entering an exciting growth phase and look forward to sharing how our technology, early clinical success, and expanding partnerships position SILQ to transform implantable device safety and performance. If you would like to learn more about SILQ Technologies and join us for the presentation, we are pleased to offer complimentary guest access to all sessions utilizing the following link: 👉 https://lnkd.in/gGQYMXvb We look forward to connecting with investors and partners who share our vision for advancing a cleaner, safer future in medical technology. #MedTech #Investing #HealthcareInnovation #MaterialsScience #InfectionPrevention #SILQTechnologies #KeiretsuForum
-
We are proud to share that Dr. Richard B. Kaner, distinguished professor at UCLA, Dr. Myung Ki Hong Endowed Chair in Materials Innovation, and Co-Founder and Board Member of Silq Technologies Corporation, presented at the 2025 Packard Fellows Science & Engineering Conference hosted by the David and Lucile Packard Foundation on September 2, 2025. Dr. Kaner’s pioneering research in advanced polymers, carbon-based energy storage, and superhard refractory materials reflects the same world-class innovation that underpins Silq’s platform. These breakthroughs are more than academic - they are the foundation of technologies we are actively translating into commercial solutions for healthcare, industry, commerce, sustainability, and beyond. At Silq, our mission is clear: ✅ Improve patient outcomes by reducing complications and costs in healthcare ✅ Unlock new markets through differentiated surface and materials technologies ✅ Build long-term value by partnering with industry leaders and scaling innovations into multi-billion-dollar markets Dr. Kaner’s recognition as a Packard Fellow highlights the caliber of science driving Silq Technologies forward. Together, we are bridging the gap between cutting-edge research and high-impact commercialization - creating a cleaner, healthier world and compelling opportunities for our partners and investors. #MaterialsScience #Innovation #InvestorImpact #SilqTechnologies #Commercialization #PackardFellows